Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
used in the treatment of hemorrhaging patients with thrombocytopenia . These products offer increased platelet concentrations at decreased volumes, longer storage shelf life, and decreased exposure ...
in the treatment of immune thrombocytopenia , data in other clinical settings are emerging . In the bone marrow transplant setting, secondary failure of platelet recovery and persistent thrombocytopenia are associated ...
the groups who received romiplostim versus placebo or other standard-of-care treatments . Yet, as after-market experience with thrombopoietin receptor agonists increases , there are emerging reports of increased ...
trials. Thus, lusutrombopag represents a promising emerging therapeutic option for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure ...
platelet count remained below 50,000/µL, we started thrombopoietin receptor agonist treatment with eltrombopag (12.5 mg/day) for thrombocytopenia . Although the platelet count increased , the patient ...
undergoing a procedure. Patients with CLD may have thrombocytopenia , increasing the risk of periprocedural bleeding. Prophylactic platelet transfusions used to reduce this risk have limitations including lack ...
therapy), there are causes of acute-onset thrombocytopenia that mandate emergent work-up and treatment . When APS-related thrombocytopenia does require therapy, the approach must be individualized (requiring ...
. Romiplostim (AMG 531, Nplate™) was designed to evade the immune response to recombinant thrombopoietin and offer a new method of treatment for patients with immune thrombocytopenia (ITP), an “orphan” disease ...
without the need for treatment . For the majority of patients who do undergo treatment , first‐line therapies, including corticosteroids, are effective in increasing platelet counts, although long‐term use ...
investigators to target this receptor for the treatment of chemotherapy-induced thrombocytopenia and other medical disorders characterized by extremely low platelet counts. As a potent stimulator of platelet ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!